Moderna, Inc. (ETR:0QF)

Germany flag Germany · Delayed Price · Currency is EUR
23.97
-0.73 (-2.94%)
At close: Jun 5, 2025, 5:30 PM CET
-81.57%
Market Cap 9.45B
Revenue (ttm) 2.94B
Net Income (ttm) -3.11B
Shares Out n/a
EPS (ttm) -8.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 715
Average Volume 552
Open 24.09
Previous Close 24.69
Day's Range 23.68 - 24.23
52-Week Range 20.18 - 147.06
Beta 1.86
RSI 55.48
Earnings Date Jul 31, 2025

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Deutsche Börse Xetra
Ticker Symbol 0QF
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

Moderna agrees to true placebo-controlled trial of new COVID vaccine, Kennedy says

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true placebo-controlled trial of its new COVID-19 vaccine.

2 days ago - Reuters

This Is What Whales Are Betting On Moderna

Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ: MRNA) revealed 20 unusual trades. Delving into the details, we found 40% of trad...

2 days ago - Benzinga

Moderna, favored by the first Trump administration for its Covid-19 vaccine, is now in trouble as Trump 2.0 shifts its position on vaccine-making

The biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.

3 days ago - WSJ

What you need to know about Moderna’s new COVID vaccine, just approved by the FDA

The shot had previously been approved for everyone 12 and older. Now, there are limits.

3 days ago - Fortune

Moderna Stock Is Trading Higher Monday: What's Going On?

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Monday after the ... Full story available on Benzinga.com

3 days ago - Benzinga

Top Stock Movers Now: Ford, Cleveland-Cliffs, Moderna, and More

U.S. equities were mixed at midday after China accused the U.S. of violating a trade deal the two countries reached last month.

3 days ago - Investopedia

Moderna Stock Climbs as FDA Approves New COVID-19 Vaccine

Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.

3 days ago - Investopedia

Moderna Stock Is Rising. A New Covid Vaccine Is Coming for Some People.

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.

3 days ago - Barrons

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s (NASDAQ: MRNA) mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged...

3 days ago - Benzinga

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.'s MRNA mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 year...

3 days ago - Benzinga

Stocks making the biggest premarket moves: Cleveland-Cliffs, Nucor, Moderna, Tesla and more

These are the stocks posting the largest moves in the premarket.

3 days ago - CNBC

Marjorie Taylor Greene slams FDA green lighting of mNEXSPIKE COVID-19 vaccine: 'Not MAHA at all!!!'

Rep. Marjorie Taylor Greene slams FDA green lighting of Moderna's mNEXSPIKE COVID-19 vaccine, describing the move as "Not MAHA at all!!!' in a post on X

3 days ago - Fox News

FDA grants limited approval to new Covid vaccine from Moderna

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 and older, as well as people ages 12 to 64 with at least one medical conditi...

4 days ago - NBC News

US approves new Moderna Covid jab for over-65s

WASHINGTON - The US Food and Drug Administration has approved Moderna’s next-generation Covid-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the r...

6 days ago - Bangkok Post

New Covid vaccine approved by US FDA: Here's all about it

The US FDA has approved Moderna's new COVID-19 vaccine, mNEXSPIKE, amidst emerging coronavirus variants. It is approved for adults 65 and older, and individuals aged 12-64 with underlying risk factors...

6 days ago - The Times of India

US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for all individuals aged 65 and above, the company said on Saturday, the first endorsement since the regul...

6 days ago - Reuters

Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE

mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has...

6 days ago - Wallstreet:Online

Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE

mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has...

6 days ago - Accesswire

Trump Administration Cancels $600 Million Contract to Develop Bird Flu Vaccine

The administration cited concerns about mRNA technology; however, Moderna says the vaccine causes a "rapid, potent and durable immune response" to the virus

7 days ago - Yahoo

HHS cancels Moderna contract for development of bird flu vaccine for humans

The Department of Health and Human Services announced this week that it had canceled its contract with Moderna to develop a bird flu mRNA vaccine for humans. In a statement, the department wrote that ...

7 days ago - CNBC Television